Evidence map›Paper›PMID 39384644›Full record

ArticlePediatric nephrology (Berlin, Germany)2025

IPNA consensus definitions for clinical trial outcomes in steroid-resistant nephrotic syndrome.

Pankaj Hari, Priyanka Khandelwal, Olivia Boyer, Rajendra Bhimma, Francesco Cano, Martin Christian, Ali Duzova, Kazumoto Iijima, Hee Gyung Kang, Shen Qian and 7 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pankaj HariDivision of Pediatric Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India. pankajhari@hotmail.com.
Priyanka KhandelwalDivision of Pediatric Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Olivia BoyerCentre de Référence MARHEA, Institut Imagine, Néphrologie Pédiatrique, Université Paris Cité, Hôpital Necker - Enfants Malades, Paris, France.
Rajendra BhimmaDepartment of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa.
Francesco CanoDepartment of Nephrology, Luis Calvo Mackenna Children's Hospital, University of Chile, Santiago, Chile.
Martin ChristianNottingham Children's Hospital, Nottingham University Hospitals, Nottingham, UK.
Ali DuzovaDivision of Pediatric Nephrology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Kazumoto IijimaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Hee Gyung KangDivision of Pediatric Nephrology, Department of Pediatrics, Seoul National University Children's Hospital & Seoul National University College of Medicine, Seoul, Korea.
Shen QianClinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hesham SafouhPediatric Nephrology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt.
Susan SamuelsDepartment of Pediatrics, Section of Pediatric Nephrology, Alberta Children's Hospital, University of Calgary, Calgary, Canada.
William E SmoyerThe Research Institute at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
Marina VivarelliLaboratory of Nephrology and Clinical Trial Center, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
Arvind BaggaDivision of Pediatric Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Franz SchaeferCenter for Pediatrics and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany.
IPNA Best Practices and Standards Committee and c4c Pediatric Nephrology Expert Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Assessment of the true impact of therapeutic interventions is a challenge in the absence of universal, standardized definitions for clinical trial endpoints in children with kidney diseases. Steroid-resistant nephrotic syndrome (SRNS) is a difficult kidney disease to treat, with unremitting disease progressing to kidney failure. Currently, available therapies result in suboptimal cure rates. Clinical trials with innovative, targeted treatments will likely be conducted for this disease in the foreseeable future. An international consortium of the IPNA Best Practices and Standards Committee and the Pediatric Nephrology Expert Group of the conect4children (c4c) network developed through consensus, standardized, internationally acceptable definitions for trial outcomes for SRNS. The endpoint definitions were formulated for use with urine protein to creatinine ratios and estimated glomerular filtration rates. Definitions of complete remission, partial remission, non-remission of disease, reduction in proteinuria, kidney disease progression, kidney failure, and composite kidney outcome were refined using an iterative process until a consensus was achieved.

Indexed as

Clinical Trials as TopicNephrotic SyndromeChildDisease ProgressionDrug ResistanceEndpoint DeterminationGlomerular Filtration RateHumansProteinuriaRemission InductionSteroidsTreatment OutcomeSteroidsEndpointEstimated glomerular filtration rateKidney failureProteinuriaRemission

Identifiers

PMID39384644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.